ARGENX SE
No SEC Form 4 filings for $ARGX in the last 30 days.
Argenx said it is partnering with Monash University and Myostellar to develop muscular therapies, citing a new research collaboration that expands its access to Australia’s research community. The announcement is attributed to argenx’s general manager for Australia, Kathryn Evans.
argenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
Argenx (ARGX) said it will acquire Forte Biosciences (FBRX) for $77 per share, announced July 27. The article says FBRX began unusual price movement on June 29, weeks before the deal, and notes similar trading activity in ARGX. It cites company valuations of about $1.06 billion for FBRX and $54.57 billion for ARGX.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ARGX (ARGENX SE). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent ARGX coverage spans mergers & acquisitions, technology and sector analysis.
The collaboration is incremental R&D news with limited near-term financial impact, but it can support longer-dated pipeline optionality.
Deal initiation increases near-term takeover probability and creates spread and event-risk dynamics for ARGX holders.
As the acquirer, ARGX’s near-term move is likely driven by deal premium, integration expectations, and any financing/regulatory overhang.
A biotech acquisition can re-rate the acquirer’s pipeline and growth profile, but integration and valuation risks remain.
The article discusses Argenx’s $2.2 billion bet via a deal with Forte Biosciences, focused on Forte’s FB102 anti-CD122 antibody for autoimmune diseases including celiac, vitiligo, and alopecia areata. It notes early celiac data and expected clinical readouts later in the year, while citing share pressure from an equity raise and delayed vitiligo timing.
alphai scores every news story that mentions ARGX with an AI model for sentiment and relevance, and aggregates insider trades from ARGENX SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Argenx said it is partnering with Monash University and Myostellar to develop muscular therapies, citing a new research collaboration that expands its access to Australia’s research community. The announcement is attributed to argenx’s general manager for Australia, Kathryn Evans.
2 min readargenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
5 min readArgenx (ARGX) said it will acquire Forte Biosciences (FBRX) for $77 per share, announced July 27. The article says FBRX began unusual price movement on June 29, weeks before the deal, and notes similar trading activity in ARGX. It cites company valuations of about $1.06 billion for FBRX and $54.57 billion for ARGX.
6 min readA weekly healthcare roundup cites multiple corporate events: Cipla and Viatris received U.S. FDA approvals, Boston Scientific announced job cuts, argenx agreed to acquire Forte Biosciences, and Johnson & Johnson and GSK reached deal terms. It highlights regulatory, M&A, and restructuring developments that can affect sector sentiment and individual stock performance.
4 min readThe article discusses Argenx’s $2.2 billion bet via a deal with Forte Biosciences, focused on Forte’s FB102 anti-CD122 antibody for autoimmune diseases including celiac, vitiligo, and alopecia areata. It notes early celiac data and expected clinical readouts later in the year, while citing share pressure from an equity raise and delayed vitiligo timing.
3 min readArgenx agreed to acquire Forte Biosciences for $2.2B to expand its immunology portfolio. The deal centers on Forte’s anti-CD122 antibody FB102, which showed Phase Ib vitiligo results with 29.6% mean FVASI improvement at week 24 (p=0.020). Argenx plans a $77 per share cash tender offer, expected to close in Q3.
6 min readSimply Wall St reports argenx (ARGX) agreed to acquire Forte Biosciences in an all-cash deal worth about $2.2b, focused on Forte’s anti-CD122 antibody program FB102. The article cites argenx share performance and valuation views, including a narrative fair value of €686.43 vs €789.80 last close, implying about 15% overvaluation.
6 min readargenx agreed to acquire Forte Biosciences for about $2.2bn total equity value. The deal, approved by both boards, is expected to close in Q3 2026 subject to conditions. argenx will tender for all Forte shares at $77 each, an ~86% premium. Forte’s lead asset FB102 (anti-CD122) is in Phase Ib and plans Phase II data in 2H 2026.
4 min readargenx agreed to acquire Forte Biosciences for about $2.2bn in cash. It will launch a tender offer at $77 per Forte share, an 86% premium to the 9 July VWAP after Phase 1b vitiligo results. The deal is expected to close in Q3, subject to tendering and US antitrust review. Forte’s lead FB102 targets CD122.
7 min readForte Biosciences (FBRX) shares rose about 40% after argenx (ARGX) agreed to buy the clinical-stage biotech in an all-cash deal valued around $2.2 billion, according to the companies. The stock was trading near $76.45 on Monday, up about $21.67 from the prior close.
1 min read
